Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alcon Inc (NY: ALC )

78.74 -0.10 (-0.13%)
Streaming Delayed Price Updated: 12:30 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 514,354
Open 78.32
Bid (Size) 78.74 (2)
Ask (Size) 78.76 (1)
Prev. Close 78.84
Today's Range 78.30 - 78.88
52wk Range 69.44 - 88.23
Shares Outstanding 489,219,355
Dividend Yield 0.30%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population 
Via MarketBeat
Alcon Publishes Agenda for 2024 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire

Performance

YTD
+2.21%
+2.21%
1 Month
-4.71%
-4.71%
3 Month
+3.20%
+3.20%
6 Month
+13.07%
+13.07%
1 Year
+10.28%
+10.28%

More News

Read More
Alcon Inc. (NYSE: ALC) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
From Alcon Inc. Corporate
Via Business Wire
What 6 Analyst Ratings Have To Say About Alcon
Via Benzinga
The Latest Analyst Ratings for Alcon
Via Benzinga
Why Medical Device Company Alcon Shares Are Sliding Today
Via Benzinga
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
From Alcon Inc. Investors
Via Business Wire
Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month
Via Benzinga
Buy This Ophthalmology Stock But Sell This One, Says Bernstein Analyst: 'Innovation Is Key'
Via Benzinga
Good News For Dry Eye Disease Patients: Eye Care Focused Alcon's Treatment Shows Encouraging Benefit In Late-Stage Trials
Via Benzinga
Where Alcon Stands With Analysts
Via Benzinga
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
From Alcon Inc. Investors
Via Business Wire
Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
Intel To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
US Stocks On Track To Build On Gains As Traders Await A Batch Of Data; Can Market Resist Profit Taking?
Via Benzinga
Topics Economy
Exposures Interest Rates
Varex Imaging Reports Weak Sales, Joins Alcon, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Alcon Reports Third Quarter 2023 Results
From Alcon Inc. Investors
Via Business Wire
Alcon Gears Up For Q3 Print; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts
Via Benzinga
Alcon Showcases Cloud-based Planning and World-class Digital Technologies During AAO 2023
From Alcon Inc. Investors
Via Business Wire
Alcon Launches TOTAL30 Multifocal Contact Lenses for Patients with Presbyopia
From Alcon Inc. Investors
Via Business Wire
Cataract Surgery with Alcon’s AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependence
From Alcon Inc. Corporate
Via Business Wire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
Via FinancialNewsMedia
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.